⚡ Quick Start — If You Read Nothing Else

The most important things to understand right now, in plain words.

CJD is rare, fast-moving, and very serious. Creutzfeldt-Jakob disease is the most common human prion disease. It causes a rapidly progressing decline — usually over weeks to months — and it is, at this time, incurable and fatal. We will not pretend otherwise. But understanding it can help you make good decisions and protect your loved one’s comfort and dignity.
First, make sure it is really CJD. Several treatable conditions can look almost exactly like CJD in the early weeks — most importantly autoimmune encephalitis, where the immune system attacks the brain and which often can be treated. Insist the team has tested for and ruled these out, including an autoimmune antibody panel, before the diagnosis is accepted.
RT-QuIC plus MRI usually confirm it. A spinal-fluid test called RT-QuIC can detect the abnormal prion protein with very high accuracy, and a brain MRI (with a sequence called DWI) shows a typical pattern. Together with the clinical picture, these are the modern tools doctors rely on.
There is no cure, so care focuses on comfort. No medicine stops or reverses CJD. What medicine can do is ease symptoms — muscle jerks, agitation, pain, seizures — and keep your loved one safe, comfortable, and surrounded by the people they love.
It is NOT spread by ordinary contact. You cannot catch CJD by hugging, kissing, sharing meals, or caring for someone day to day. Ordinary hygiene is enough. Special precautions only apply to certain medical and surgical procedures.
Some forms are genetic — counseling is available. About one in ten cases is inherited through a change in the PRNP gene. If your family is affected, genetic counseling can help you understand the risks and the very personal choice of whether relatives wish to be tested.
Palliative care and hospice are your allies. Bringing in palliative care early — not at the very end — means better symptom control and more support for the whole family. These teams are experts in comfort and dignity.
You are not alone. The CJD Foundation (HelpLine 800-659-1991) supports families through every step, and national surveillance centers offer free testing and answers. Reach out early.

▼ Collapse

Understanding CJD & Prion Disease

If you are reading this, you or someone you love has likely just heard the words “Creutzfeldt-Jakob disease” for the first time — perhaps in a hospital corridor, perhaps after weeks of frightening, fast-moving changes that no one could explain. This is one of the hardest diagnoses in all of medicine to receive. We want to be honest with you, and we also want to be gentle. The pages that follow are written to help you understand what is happening, to make sure nothing treatable has been missed, and to help you give your loved one the most comfort and dignity possible.

What is a prion?
Your brain is full of a normal, harmless protein called the prion protein (its everyday name is PrP). Think of a protein as a tiny piece of origami — it only works when it is folded into exactly the right shape. In prion disease, one of these proteins folds into the wrong shape. The misfolded version is the “prion.” What makes prions so unusual is that the misfolded protein can touch a normal, correctly folded protein and force it to misfold too — like one falling domino knocking over the next. This chain reaction slowly damages and destroys brain cells, leaving microscopic sponge-like holes in brain tissue. That is why these illnesses are also called spongiform encephalopathies.

Creutzfeldt-Jakob disease (CJD) is the most common human prion disease, but it is still rare — affecting roughly one to two people in every million each year worldwide. It is named after the two German doctors who first described it in the 1920s. Because it is so uncommon, many doctors will only see a single case in their entire careers, which is one reason a referral to a specialist center can be so valuable.

What sets CJD apart from more familiar conditions like Alzheimer’s disease is its speed. Alzheimer’s typically unfolds over many years. CJD moves in weeks to months. A person who was working, driving, and fully themselves a few months ago may, in a tragically short time, lose the ability to walk, speak, and recognize their surroundings. This rapid course is devastating, but it is also one of the clues doctors use to recognize the disease.

Almost every other infectious disease you have heard of — the flu, COVID, strep throat — is caused by a germ that carries its own genetic instructions (DNA or RNA): bacteria, viruses, fungi, parasites. Prion diseases are different. There is no virus, no bacterium, no genetic material from an outside germ. The “agent” is simply a misfolded version of one of your body’s own proteins. This was such a strange idea when it was first proposed that it took decades for scientists to accept it; the researcher who championed it, Stanley Prusiner, eventually won the Nobel Prize for the discovery.

Because there is no germ to kill, the usual tools — antibiotics, antivirals — do nothing. And because the misfolded protein is extraordinarily tough, it resists the ordinary methods hospitals use to sterilize instruments. This is why CJD requires special — though uncommon — precautions in surgical settings, even though it poses no danger in everyday life. We explain this fully in the Transmission & Infection Control section.

CJD is the most common, but the prion-disease family includes several named conditions. You may hear these mentioned by doctors or in your own reading:

Fatal Familial Insomnia (FFI) — a genetic prion disease whose first symptom is often severe, worsening insomnia, along with changes in the body’s automatic functions (blood pressure, temperature, heart rate).
Gerstmann-Sträussler-Scheinker syndrome (GSS) — another inherited prion disease, often slower than classic CJD, frequently beginning with problems of balance and coordination.
Variably protease-sensitive prionopathy (VPSPr) — a very rare sporadic form recognized more recently.
Kuru — a now essentially eliminated prion disease once seen in Papua New Guinea, historically linked to ritual practices; it is of mainly historical interest today.

Most of this guide focuses on CJD because it is by far the most common, but the principles of accurate diagnosis, comfort care, and family support apply across all of them.

Is It CJD — or Something Treatable?

The most important message in this entire guide.
In the early weeks, several treatable conditions can look almost exactly like CJD — same rapid confusion, same unsteadiness, even similar test results. The most important of these is autoimmune encephalitis, in which the body’s own immune system mistakenly attacks the brain. Unlike CJD, autoimmune encephalitis often responds to treatment — sometimes dramatically. Because the two can be so hard to tell apart at first, families should make absolutely sure the medical team has tested for and excluded these treatable causes — including a dedicated autoimmune antibody panel — before a diagnosis of CJD is accepted. Asking about this is not second-guessing the doctors; it is exactly what a good neurologist would want you to ask.

A rapidly progressive dementia — a fast decline in thinking, memory, and behavior over weeks to months — is the pattern that makes doctors think of CJD. But that same pattern can be caused by a long list of other conditions, and some of those conditions can be treated, slowed, or even reversed. A careful neurologist works through this list deliberately, precisely because missing a treatable cause would be tragic.

Treatable look-alike	What it is	How it’s checked
Autoimmune (and paraneoplastic) encephalitis	The immune system attacks the brain; can cause rapid confusion, seizures, movement changes, and behavior changes. Often treatable with steroids, immune therapies, or treating an underlying tumor.	Blood and spinal-fluid autoimmune antibody panels (for example NMDA-receptor, LGI1, CASPR2 antibodies), MRI, and a search for any hidden cancer.
Infections	Certain brain infections (viral, bacterial, fungal) can mimic a fast dementia.	Spinal-fluid analysis, blood tests, imaging.
Vitamin deficiencies	Severe deficiency of vitamin B12 (or thiamine) can cause confusion and neurological decline.	Simple blood tests; corrected with supplementation.
Thyroid disease	A severely under- or over-active thyroid — including a rare autoimmune brain condition linked to thyroid antibodies — can imitate CJD.	Thyroid blood tests; thyroid antibodies.
Toxins, medications & metabolic problems	Certain poisonings, drug effects, liver or kidney failure, and electrolyte problems.	Blood tests, medication review, organ-function tests.
Other rapidly progressive dementias	Some atypical, fast forms of Alzheimer’s, Lewy body, or vascular disease; certain cancers affecting the brain.	MRI, spinal fluid, sometimes specialized biomarkers.

The good news within hard news: the very tests that confirm CJD — especially the spinal-fluid RT-QuIC test — are also extremely good at telling CJD apart from these mimics. A positive RT-QuIC strongly supports CJD; a thorough workup that comes back negative for treatable causes and positive on the CJD-specific tests gives families a diagnosis they can, sadly, trust. If the picture is unclear, a specialist prion center or autoimmune neurology team is the right next step.

A note on advocacy. It is completely appropriate — encouraged, even — to ask the medical team directly: “Have we tested for autoimmune encephalitis and other treatable causes? Has the autoimmune antibody panel been sent? Should we get a second opinion from a center that sees prion disease and rapidly progressive dementia?” The best clinicians welcome these questions.

The Four Main Types

CJD is not a single illness but a family of closely related ones, grouped by what causes the prion protein to misfold. Knowing which type is involved matters — especially for families, because one of the four can be inherited. Here they are in plain terms; the Diagnosis section covers each in more depth.

Type	Roughly how common	Cause	Who it tends to affect
Sporadic CJD (sCJD)	About 85% of all cases — the great majority	No known cause; the protein appears to misfold spontaneously, seemingly by chance	Usually adults in their 60s; not inherited, not caught from anyone
Genetic / familial prion disease	Roughly 10–15% of cases	An inherited change (mutation) in the PRNP gene; includes FFI and GSS	Runs in families; can appear at a wider range of ages
Iatrogenic CJD (iCJD)	Now very rare	Historically passed through certain medical procedures (see below)	Almost eliminated by modern safeguards
Variant CJD (vCJD)	Now extremely rare	Linked to eating beef from cattle with “mad cow disease” (BSE)	Mostly the UK in the 1990s–2000s; tended to affect younger people

The two reassuring points families ask about most.
First, sporadic CJD — the most common form — is not inherited and is not contagious in everyday life. If your loved one has sporadic CJD, other family members are not at increased risk. Second, the two forms that worried the public most — the “mad cow” variant (vCJD) and the medical-procedure form (iatrogenic) — are now extraordinarily rare thanks to changes in farming, food safety, and surgical practice over the past few decades.

What This Diagnosis Means

We believe honesty is its own kind of kindness, so we will not soften the facts: CJD is currently incurable, and it is fatal. For most people with sporadic CJD, the illness runs its course over a matter of months — commonly within four to six months of the first clear symptoms, though some forms move faster and a few (especially certain genetic forms) move more slowly. Hearing this is shattering. There is no way to make those words easy.

But within that hard truth, there is real and meaningful room for action — things you can do that genuinely matter:

You can make sure the diagnosis is right — ruling out treatable look-alikes, so that no opportunity is missed.
You can shape the kind of care your loved one receives — choosing comfort, presence, and dignity over aggressive interventions that would not help.
You can keep your loved one comfortable — modern palliative medicine is very good at controlling the symptoms of CJD.
You can be present. Even as words slip away, many families find that touch, familiar voices, favorite music, and simple presence still reach their loved one. This time, however painful, can also hold tenderness.
You can contribute to others’ futures — through surveillance, brain donation, and (for some) research participation, families have made every advance in understanding this disease possible.

Grief often begins before the loss — this is called anticipatory grief, and it is normal. So is exhaustion, anger, numbness, and moments of unexpected closeness. There is no “right” way to feel. The Caregiver Guidance and Honest Conversation About Hope sections are written for exactly this.

Questions to Ask Your Doctor — Getting Started

Bring this list to the first appointments. You can write the answers right on a printed copy.

What makes you think this is Creutzfeldt-Jakob disease rather than something else?
Have we tested for and ruled out treatable causes — especially autoimmune encephalitis? Has an autoimmune antibody panel been sent on blood and spinal fluid?
Which type of CJD do you think this is — sporadic, genetic, iatrogenic, or variant — and how will we know?
Has the RT-QuIC test been done, and has the MRI been reviewed specifically for CJD patterns?
Should we get a second opinion or referral to a specialist prion or rapidly-progressive-dementia center?
Is there any chance this form could be inherited — should we consider PRNP genetic testing, and would genetic counseling come first?
Who will be our main point of contact as things change, and how do we reach them urgently?
When should we involve palliative care — and can we start that conversation now?

Symptoms & How CJD Differs From Other Dementias

CJD usually announces itself as a combination of a fast-moving dementia together with neurological signs — especially sudden muscle jerks and loss of balance. Because the disease damages many parts of the brain at once, symptoms can be wide-ranging and can change quickly, sometimes from week to week.

The common early and progressing symptoms

Rapidly worsening thinking and memory — confusion, forgetfulness, trouble with everyday tasks, advancing far faster than in Alzheimer’s disease.
Personality and mood changes — depression, anxiety, withdrawal, irritability, or behaving out of character. Sometimes these come first, before memory problems are obvious.
Myoclonus — sudden, brief, involuntary muscle jerks, often startling and sometimes triggered by noise or touch. This is a hallmark of CJD.
Ataxia — loss of balance and coordination; an unsteady, lurching walk; clumsiness; falls.
Vision problems — blurred or double vision, trouble judging distances, or visual hallucinations; in one variety (the Heidenhain variant) visual symptoms come first.
Trouble walking and moving — stiffness, slowness, tremor, or other movement changes.
Speech and swallowing difficulty — words become harder to find and then harder to form; swallowing becomes unsafe later in the illness.

As the disease advances, it leads to a state called akinetic mutism — a phrase that simply means the person becomes unable to move purposefully (akinetic) and unable to speak (mutism), even though they may still have periods of wakefulness. This is one of the most painful stages for families to witness. The comfort-care guidance later in this guide is written with this stage very much in mind.

CJD vs. Alzheimer’s — the key difference is speed.
Alzheimer’s disease typically progresses over many years, with memory loss as the slow, leading symptom. CJD progresses over weeks to months, usually combines the fast cognitive decline with prominent movement signs (myoclonus, ataxia), and often shows changes on MRI and spinal-fluid testing that Alzheimer’s does not. When a dementia appears to be moving this fast, doctors specifically think about CJD — and about the treatable look-alikes covered in the Overview.

The Subtypes in Detail

Sporadic means “happening by chance, with no known cause.” This is by far the most common form. As best science can tell, the prion protein simply misfolds on its own, for reasons we do not yet understand — not because of anything the person did, ate, inherited, or caught. It typically appears in people in their 60s, though it can occur earlier or later.

Because it is not inherited, sporadic CJD does not put other family members at higher risk. And because it is not spread by everyday contact, families can care for their loved one safely. Sporadic CJD often progresses quickly, with many people living a matter of months after symptoms become clear. There are recognized varieties within sporadic CJD (defined by genetic and protein subtypes that doctors use behind the scenes), and one well-known variety — the Heidenhain variant — begins with visual symptoms.

A minority of prion diseases are caused by an inherited change (a mutation) in a gene called PRNP, which carries the instructions for making the prion protein. Because the faulty instructions are passed down, these forms run in families. They are usually inherited in an autosomal dominant pattern, which means a person who carries the mutation has, on average, a 50% chance of passing it on to each child.

Genetic prion disease is an umbrella that includes:

Genetic (familial) CJD — resembling sporadic CJD but with an inherited cause.
Fatal Familial Insomnia (FFI) — often beginning with progressively severe insomnia and problems with the body’s automatic functions.
Gerstmann-Sträussler-Scheinker syndrome (GSS) — often slower-moving, frequently starting with unsteadiness and coordination problems.

If a genetic form is suspected, genetic counseling is essential — both to confirm the diagnosis and to support relatives who may be weighing whether they wish to be tested. We cover this sensitive topic fully in Genetic Forms & Counseling.

“Iatrogenic” means “caused inadvertently by medical treatment.” In the past, before prions were understood, CJD was occasionally transmitted through specific medical procedures, including:

Human growth hormone prepared from the pituitary glands of deceased donors (this practice ended decades ago; growth hormone is now made synthetically).
Grafts of dura mater (the tough membrane covering the brain) taken from donors and used in surgery.
Rarely, neurosurgical instruments or corneal transplants from an affected donor.

Thanks to modern safeguards — synthetic hormones, screening of tissue donors, specialized sterilization and single-use instruments for high-risk procedures, and careful surveillance — iatrogenic CJD has become extremely rare. It is mainly important now for historical understanding and for the precautions hospitals continue to take.

Variant CJD is the form that became widely known as the human illness linked to “mad cow disease.” In cattle, the prion disease is called bovine spongiform encephalopathy (BSE). In the 1980s and 1990s, an outbreak of BSE in cattle — chiefly in the United Kingdom — was followed by cases of a new human prion disease, vCJD, believed to result from eating contaminated beef products.

Variant CJD differed from classic CJD in important ways: it tended to affect younger people (often in their 20s and 30s), frequently began with psychiatric symptoms and painful sensations, and tended to progress somewhat more slowly. Following strict controls on cattle feed and food safety, the number of cases fell dramatically. Today vCJD is extremely rare, with only a small number of cases reported worldwide in recent years.

How Doctors Confirm CJD — A Hopeful, Practical Section

This is one of the most actionable parts of the whole journey. Modern testing has improved enormously, and today doctors can usually reach a confident diagnosis during life — while at the same time ruling out the treatable look-alikes. Here are the tools they use, explained plainly.

RT-QuIC — the most important modern test

RT-QuIC (its full name is real-time quaking-induced conversion) is a remarkable spinal-fluid test that can detect the abnormal prion protein itself with very high accuracy. In simple terms, the test takes a small sample of spinal fluid (collected by a lumbar puncture, or “spinal tap”) and uses it to see whether any misfolded prion protein is present and able to trigger the tell-tale misfolding chain reaction in the lab. When RT-QuIC is positive, it strongly supports a diagnosis of CJD, and importantly it is very specific — a positive result is not usually caused by the treatable look-alikes. Research has shown RT-QuIC to be highly accurate. A version that can be performed on a brushing from inside the nose was reported by Orrú CD and colleagues, New England Journal of Medicine 2014, PMID 25099576. The diagnostic accuracy of the spinal-fluid test was shown by Bongianni M and colleagues, JAMA Neurology 2017, PMID 27942718.

MRI of the brain (with DWI)

A magnetic resonance imaging scan of the brain — particularly a sequence called diffusion-weighted imaging (DWI) — can show patterns of bright signal in specific brain regions that are characteristic of CJD. A radiologist or neurologist experienced with prion disease looks for these patterns specifically. MRI is also valuable for spotting some of the treatable look-alikes. Modern diagnostic criteria (Zerr I and colleagues, Brain 2009, PMID 19773352) give MRI a central place alongside RT-QuIC.

Older spinal-fluid markers (14-3-3 and tau)

Before RT-QuIC, doctors relied on supportive spinal-fluid markers such as the 14-3-3 protein and tau. These are released when brain cells are damaged. They are helpful as supporting evidence, but they are less specific than RT-QuIC — meaning they can be raised in other conditions too — so today they play a supporting rather than a starring role (Hermann P and colleagues, Lancet Neurology 2021, PMID 33609480).

EEG (brain wave test)

An electroencephalogram records the brain’s electrical activity through small sensors on the scalp. In some people with sporadic CJD, the EEG shows a characteristic repeating pattern. When present, this pattern is supportive; when absent, it does not rule CJD out.

Genetic (PRNP) testing

A simple blood test can look for changes in the PRNP gene. This is how genetic forms are confirmed. Because a result has implications for the whole family, this testing is best done together with genetic counseling — see Genetic Forms & Counseling.

Brain tissue (neuropathology) — the only fully definitive test

The single test that can confirm prion disease with complete certainty is examining brain tissue under a microscope, looking for the sponge-like changes and the abnormal prion protein. In almost all cases this is done at autopsy rather than by biopsy during life. Far from being only a formality, autopsy gives families a definitive answer, identifies the exact type, clarifies any genetic implications for relatives, and contributes to national surveillance and research. We discuss this gently and fully in Autopsy, Surveillance & the NPDPSC.

How the pieces fit together. No single test is used in isolation. A neurologist combines the clinical picture (the speed and pattern of symptoms), the MRI, RT-QuIC, supportive spinal-fluid markers, EEG, and — where relevant — genetic testing, while actively excluding the treatable causes. International diagnostic criteria define categories such as “probable” and “definite” CJD; a positive RT-QuIC has made confident diagnosis during life far more achievable than it was a generation ago.

Questions to Ask Your Doctor — About the Diagnosis

Which tests have been done so far — MRI with DWI, RT-QuIC, 14-3-3 and tau, EEG — and what did each show?
Was the MRI reviewed by someone experienced in recognizing CJD patterns?
Has RT-QuIC been sent, and to which laboratory? When do we expect results?
Are we confident this is not autoimmune encephalitis or another treatable cause? What still needs to be checked?
Which type of CJD does the evidence point to — and could it be a genetic form?
Would PRNP genetic testing be appropriate, and would we meet with a genetic counselor first?
At what point, if any, would a brain biopsy be considered — and what are the trade-offs?
Can you connect us with a specialist prion or rapidly-progressive-dementia center for confirmation or a second opinion?

There Is No Cure — and Why Comfort Care Matters So Much

We will say it plainly, because you deserve the truth: at this time there is no medicine that cures CJD, and no medicine that has been proven to slow it down. Several drugs were studied with great hope over the years and, sadly, did not work (we list them honestly in Failed & De-Adopted Therapies). Research continues, and we describe the most promising current directions in the next section. But for a family caring for someone now, the focus of medical care shifts from cure to something just as important and deeply meaningful: comfort, safety, and dignity.

Comfort care is real medicine.
Choosing comfort-focused care is not “giving up.” It is an active, skilled, and loving form of medicine. The symptoms of CJD — muscle jerks, agitation, pain, seizures, difficulty swallowing — can almost always be eased with the right care. A good palliative care team treats these symptoms expertly, supports the whole family, and helps make sure your loved one’s remaining time is as peaceful and dignified as possible.

Because CJD can move quickly, it helps to think and plan ahead of where the illness currently is — arranging medicines, equipment, and support before they are urgently needed. Your care team can help you anticipate the next steps so you are never caught unprepared. The symptom-by-symptom guide below describes the kinds of comfort measures commonly used. (Specific medicines and doses are always decided by the treating team for each individual.)

Symptom-by-Symptom Comfort Guide

This section describes how each common symptom of CJD is typically managed for comfort. It is meant to help you understand and discuss options with the medical team — not to replace their judgment. Every person is different, and the team will tailor everything to your loved one.

The sudden involuntary jerks of myoclonus can be distressing to watch and can disturb rest. They are usually treatable. Doctors commonly use medicines such as clonazepam, levetiracetam, or valproate (valproic acid) to reduce them. These medicines aim purely at comfort; they do not affect the disease itself. The team adjusts the choice and dose to control the jerks while keeping the person as comfortable and settled as possible.

As the brain is affected, some people become restless, anxious, frightened, or agitated — especially if they cannot understand or communicate what they are feeling. A calm, familiar environment, gentle reassurance, soft lighting, and familiar voices or music all help. When medicines are needed, the team may use anti-anxiety medicines or, carefully, low doses of other calming medicines. The goal is always comfort and peace, never sedation for its own sake. Tell the team promptly if your loved one seems frightened or in distress — this is something they can help with.

People who cannot speak can still feel discomfort, and they can still show it — through facial expressions, tension, restlessness, or changes in breathing. Sources of discomfort include stiff muscles, pressure on the skin, constipation, a full bladder, or simply being in one position too long. Palliative teams are skilled at recognizing and treating pain even when a person cannot report it, using regular repositioning, gentle handling, and pain medicines (including opioids when appropriate) titrated for comfort. Trust your instincts — you know your loved one’s expressions best, and your observations are valuable to the team.

Some people with CJD develop seizures. These are treated with anti-seizure medicines, and the team can prepare a plan — including medicines that can be given quickly at home or in a care setting — so that a seizure can be managed calmly and comfortably. Ask the team what to do and what to have on hand if a seizure occurs.

As swallowing weakens, saliva and chest secretions can build up, sometimes causing a rattling sound in the breathing that is often more distressing to families than to the person themselves. Repositioning, gentle suctioning, and medicines that dry secretions can ease this. The team will explain what is happening and what comfort measures are available.

Difficulty swallowing (dysphagia) is common as CJD advances, and it raises the risk of choking and of food or liquid going into the lungs (aspiration). A speech-language therapist can advise on safe textures and techniques while eating remains possible and enjoyable. As the illness progresses, families and the care team face gentle decisions about feeding. Many families, guided by palliative care, choose careful hand-feeding for comfort and pleasure rather than feeding tubes, which have not been shown to improve comfort or length of life in advanced, irreversible brain disease. There is no single right answer — these are deeply personal choices, and the team will help you weigh them in light of your loved one’s wishes and values. Good mouth care — keeping the lips and mouth moist and clean — brings real comfort at every stage.

When someone can no longer move freely, the skin needs protection from pressure sores: regular gentle repositioning, pressure-relieving mattresses and cushions, and keeping skin clean and dry. Earlier in the illness, when balance is failing but the person is still mobile, falls are a major risk — clear pathways, good lighting, removing trip hazards, supervised walking, and appropriate equipment all help. Occupational and physical therapists, and district or home-health nurses, can advise and provide equipment.

Sleep is often disrupted in CJD (and in Fatal Familial Insomnia, disrupted sleep is a central feature). A predictable routine, daytime light, a calm and comfortable environment, and — when needed — medicines chosen by the team can help your loved one rest. Tell the team if nights are difficult; this is something they can support, and it protects your own rest as a caregiver too.

A simple principle. If something looks uncomfortable, distressing, or new — tell the care team. There is almost always something that can be done. You do not have to figure it out alone, and you are never “bothering” them by asking.

Palliative Care & Hospice — Bring Them In Early

Two of the most helpful phone calls a family can make are to palliative care and, when appropriate, hospice. These are not the same thing, and both can be valuable.

Palliative care

Palliative care is specialized care focused on relief of symptoms and on quality of life for people with serious illness — at any stage, alongside other care. A palliative care team typically includes doctors, nurses, social workers, and chaplains. They are experts in exactly the symptoms CJD causes, and they support the family as well as the patient. Because CJD can move quickly, involving palliative care early — soon after diagnosis, not only at the very end — usually leads to better symptom control and far less crisis.

Hospice

Hospice is comfort-focused care for people who are nearing the end of life, usually provided where the person lives — at home or in a care home — though inpatient hospice settings also exist. Hospice teams provide medicines, equipment, nursing visits, and round-the-clock advice, and they support the family through the final stage and into bereavement. In the United States, hospice is a covered Medicare benefit; in many other countries hospice and community palliative services are available through the health system or charitable hospices. Ask your team how to access hospice where you live, and do not wait until a crisis — arranging it in advance brings peace of mind.

Quality of life, presence, and dignity. The aim of this stage of care is not measured in days but in comfort and connection. Familiar surroundings, gentle touch, favorite music, the voices of loved ones, photographs, a beloved pet nearby — these small things matter enormously. Many families find moments of real peace and closeness even now. Your presence is itself a form of care.

Questions to Ask Your Doctor — About Care & Comfort

Can we involve palliative care now, and how do we reach them between visits?
What is your plan for controlling muscle jerks, agitation, pain, seizures, and secretions — and what should we have at home?
How will you assess comfort and pain once our loved one can no longer tell us how they feel?
What is the safest approach to eating and swallowing now, and how will we revisit it as things change?
What is your guidance on feeding tubes versus comfort feeding for someone with advanced CJD?
What signs should prompt us to call you urgently, and who do we call after hours?
When is the right time to arrange hospice, and how do we set that up where we live?
How can we make our loved one most comfortable and peaceful day to day?

class="content-section" data-stage="advanced">

Research & Clinical Trials — An Honest Picture

Families understandably want to know whether there is anything — any trial, any experimental drug — that might help. We owe you an honest answer, and the honest answer is twofold. First: as of now, no treatment has been proven to slow or cure CJD, and the speed of the disease makes treatment trials extraordinarily difficult to conduct. Second: there is genuine, serious scientific work underway, and for the first time there are approaches aimed at the root of the disease rather than just its symptoms. Both of these things are true at once.

If you wish to explore research participation, the right first step is to speak with a specialist prion center (such as the National Prion Disease Pathology Surveillance Center in the US or the National Prion Clinic in the UK — see the directory). They will know what, if anything, is currently enrolling, whether it is suited to your loved one’s situation, and what participation would realistically involve. Be cautious of any clinic or product — especially online — that promises a cure or charges large fees for unproven prion “treatments”; these are not legitimate.

Where the most promising research is focused. The leading scientific strategy is to lower the amount of prion protein the body makes — on the logic that if there is less normal prion protein available to be corrupted, the disease cannot spread through the brain. The main tools being developed for this are called antisense oligonucleotides (ASOs). These are described in the section below. They are investigational and not approved, but they represent the most hopeful direction in decades.

Understanding How CJD Progresses: A Week-by-Week Guide for Families

Every family wants to know what to expect and when. CJD is not a single experience — its speed and pattern vary by type, by person, and by the specific molecular variant driving the disease. But having a rough map can help you plan, grieve, and be fully present for your loved one in each phase. This section describes the typical course for each major form and explains why some people’s journeys differ significantly from others.

Sporadic CJD (sCJD) runs its course over 4–6 months in most cases, though some individuals decline in weeks and others survive a year or more. The illness tends to move through recognizable phases, though not everyone follows the same path in the same order, and not every symptom appears in every person.

Early phase (approximately weeks 1–6): Most families notice that something is wrong before anyone uses the word “dementia.” Common early signs include unusual fatigue, difficulty finding words in conversation, forgetting recent events (appointments, names, directions), unsteady walking or balance problems, and sometimes visual disturbances — things looking blurry, doubled, or distorted in unfamiliar ways. Mood changes are common too: depression, anxiety, irritability, or a subtle personality shift that is hard to name but unmistakable to those who know the person well. Some people report pain or unusual sensations (tingling, burning, electric feelings) in their limbs. At this early stage, the right diagnosis has often not yet been made — most people see multiple doctors over several weeks before anyone considers prion disease. This early phase can easily be mistaken for a particularly bad stretch of forgetfulness, a balance disorder, depression, or anxiety, and the remarkable speed of change may not yet be fully apparent.

Middle phase (approximately weeks 4–16): By this point, the decline is usually unmistakable and alarming in its speed. The cognitive problems that seemed manageable weeks ago are now significant: following a conversation becomes difficult, complex tasks become impossible, and familiar faces are sometimes no longer recognized. Myoclonus — sudden, brief, involuntary jerks of the muscles — typically appears in this phase. These jerks can be dramatic, particularly when triggered by a sudden noise or unexpected touch (startle-sensitive myoclonus), and they are one of the most distinctive features that leads doctors to suspect CJD. Walking becomes unsafe or impossible. Some people begin speaking in disjointed words or phrases rather than full sentences, and communication becomes increasingly one-sided. Incontinence often develops. Despite all of this, many people continue to recognize and respond to loved ones during this phase — connection remains possible even as independence is lost. These weeks are often the most emotionally grueling for caregivers: the person they love is clearly still present in some ways, while simultaneously being transformed by the disease.

Late phase (approximately weeks 8–24): A state called akinetic mutism marks the final weeks of most sCJD courses. The person lies quietly, no longer speaking purposefully or making intentional movements, though they may sometimes open their eyes, turn toward a familiar voice, or show brief moments of what seems like awareness. Myoclonus may continue or gradually lessen. The brain is profoundly damaged at this stage, but there is meaningful evidence — from neurological science and from the bedside observations of experienced nurses and palliative doctors — that the ability to sense familiar voices, music, and the comfort of touch may persist even in akinetic mutism. Continuing to speak softly, hold hands, play familiar music, and offer gentle physical presence remains meaningful and is not futile.

When death comes: CJD itself does not always cause death directly. The brain’s progressive loss of function leads to loss of the ability to swallow safely, which greatly increases the risk of food, liquid, or secretions entering the lungs. Aspiration pneumonia — a lung infection from this material — is the most common direct cause of death. Urinary tract infections, pressure injuries, and cardiovascular complications are also common contributors. Hospice and palliative care teams manage these final complications with a strong focus on comfort, preventing unnecessary suffering, and supporting the entire family through what is usually a deeply difficult final stretch.

Doctors classify sporadic CJD by two laboratory characteristics: the genetic letters at a specific position on the PRNP gene called codon 129 (which can be M for methionine or V for valine, inherited independently from each parent) and the shape of the misfolded prion protein (the PrP-Sc type). These combine into subtypes — most commonly MM1, VV2, MV2, and others — that meaningfully affect how the illness presents and how long it lasts. Families do not need to learn this terminology, but it is why one person’s CJD course can look quite different from another’s even though both have the same disease:

MM1 / MV1 (most common, over half of cases): The “classic” rapid course described above. Dementia and myoclonus are prominent early. The EEG often shows characteristic patterns. Median course approximately 3–5 months from symptom onset. Most guides and medical descriptions of CJD primarily describe this subtype because it is the most common.
VV2 (second most common, about 15–20% of cases): The “cerebellar” form. Walking and balance problems come first and prominently, before obvious memory loss. Doctors sometimes describe this as the Oppenheimer–Brownell variant. It may be missed early because prominent gait problems can seem like orthopedic or vestibular conditions. Slightly longer median course, approximately 5–8 months.
MV2 (about 10–15% of cases): Intermediate presentation with both ataxia and cognitive decline. Course often longer than MM1 — some MV2 cases last 12–18 months or more. Families often describe a somewhat slower descent than MM1, though the ultimate outcome is the same.
MM2 cortical and thalamic variants (less common): The thalamic variant (sometimes called sporadic fatal insomnia because it resembles FFI) can produce prominent sleep disturbance and autonomic symptoms alongside cognitive decline, with a course that may extend beyond a year. The cortical variant produces progressive dementia with a longer course than MM1.
VV1 (rare): The rarest subtype, typically affecting younger individuals and with a longer course. The dementia is the dominant feature, and it may be mistaken for other causes of dementia until the progression becomes evident.

The molecular subtype cannot be determined by external examination or standard clinical tests — it requires specific laboratory analysis of brain tissue, usually at autopsy. For most families, the practical importance of subtypes is understanding why the doctor might give a range of prognosis rather than a single number. Knowing that VV2 typically lasts a bit longer than MM1, or that MV2 has more time, can help families plan — though individual variation means these are guides rather than guarantees.

Variant CJD (vCJD), the form linked to eating beef from BSE-infected cattle (primarily UK and Europe during the 1980s and 1990s), follows a distinctly different course from sporadic CJD. It is extremely rare today — fewer than 250 cases have ever been confirmed worldwide — but its features are important to understand, particularly for families of younger people.

Who develops vCJD: Unlike sporadic CJD, which typically affects people in their 60s and 70s, vCJD has a much younger age of onset — most cases have been in people in their 20s and 30s, with the youngest confirmed case in a teenager. This demographic reality means that vCJD losses are often the loss of a child, a sibling, or a young parent.
Psychiatric prodrome — months before neurology: vCJD typically begins with 4–6 months of psychiatric symptoms — depression, anxiety, social withdrawal, and behavioral changes — before neurological signs emerge. This psychiatric prodrome can lead to months of evaluation and treatment for mental illness before a neurological condition is considered. Families often look back and recognize this period as the true beginning of the illness, though at the time it seemed like “depression” or “a breakdown.”
Neurological phase: Cerebellar ataxia (unsteady gait, clumsiness), painful sensory symptoms in the limbs, and cognitive decline follow the psychiatric phase. Memory loss is often less prominent early than in sporadic CJD. As the disease advances, myoclonus, akinetic mutism, and the same terminal trajectory seen in sCJD develop.
Longer course: vCJD typically runs 12–18 months rather than the 4–6 months of sCJD. This longer trajectory can feel simultaneously like more time with a loved one and like a more prolonged experience of watching them decline. Caregivers of vCJD patients often face a distinctly extended caregiving period with its own particular demands.
Pulvinar sign on MRI: A distinctive pattern on brain MRI — bilateral high signal in the pulvinar (a part of the thalamus) — is characteristic of vCJD and is one of the imaging features that supports this diagnosis. This feature, along with the younger age and psychiatric prodrome, helps distinguish vCJD from sporadic CJD in the clinical evaluation.
The emotional and social dimension: Losing a child or young sibling to vCJD carries its own particular grief — careers not lived, children left without a parent, parents outliving children. The CJD Foundation and peer support communities can connect families with others who have specifically experienced vCJD loss, which has features that differ meaningfully from the more common sporadic CJD experience.

Failed & De-Adopted Therapies — What Has Not Worked

Over the years, several drugs were tried in CJD, sometimes with intense hope and media attention. We list them here honestly, because families deserve to recognize them — and because you may encounter people online still promoting them. None of these has been shown to extend survival or change the course of the disease in proper studies.

Therapy	What was hoped	What studies found
Quinacrine	An old antimalarial drug that showed activity against prions in the laboratory.	In people, it did not improve survival or outcomes and could cause side effects. No longer used as a treatment.
Pentosan polysulfate	A compound delivered directly into the brain’s fluid, hoped to slow the disease.	An invasive approach with no clear, proven benefit on the disease course; not an established treatment.
Doxycycline	A common antibiotic that showed promise in laboratory and early observations.	A carefully conducted randomized trial found it did not extend survival in CJD (Haïk S and colleagues, Lancet Neurology 2014, PMID 24411709).

We share this not to take away hope, but to direct hope where it can do good — toward excellent comfort care now, and toward legitimate, science-based research for the future. Knowing what has been tried and disproven can also protect grieving families from being misled.

Prion-Lowering (ASO) Research — The Most Promising Direction

The most hopeful area of current research aims at the disease’s root cause rather than its symptoms. The idea is elegantly simple: prion disease spreads when misfolded prion protein corrupts normal prion protein. If you could safely reduce the amount of normal prion protein the brain produces, there would be less raw material for the disease to corrupt — potentially slowing or even preventing it.

The leading tools for this are antisense oligonucleotides, usually shortened to ASOs. An ASO is a small, custom-designed strand that interferes with the genetic instructions for making a specific protein — in this case, telling the body to make less prion protein. This same class of medicine has already been approved for certain other neurological diseases, which gives scientists a foundation to build on. For prion disease, ASOs remain investigational and not approved; they are in early-stage development and research, not routine use.

Research in people who carry a mutation but are not yet sick. Because the speed of established CJD makes treatment so hard to study, some of the most important research focuses on people who carry a PRNP mutation but have not yet developed symptoms (“pre-symptomatic” research). The hope is that lowering prion protein before the disease takes hold could one day delay or prevent it in at-risk families. This work is ongoing and deeply personal; families affected by genetic prion disease can ask a specialist prion center about current studies. Recent reviews summarize the state of genetic prion disease and these emerging approaches (Mead S and colleagues, Lancet Neurology 2026, PMID 41579904).

We want to be careful here: this research is genuinely promising, but it is not yet a treatment, and it cannot be presented as one. Sharing it is about honesty in the other direction — honoring the real scientific progress being made, much of it driven by affected families themselves.

Genetic Forms, Counseling & Pre-Symptomatic Testing

If your family is touched by a genetic (inherited) prion disease, you face questions that no family should have to face — about risk, about testing, about children and grandchildren, about how much you want to know. There are no wrong answers here, only personal ones, and you deserve expert, compassionate guidance.

How inheritance works, in plain terms

Genetic prion disease is caused by a change in the PRNP gene and is usually inherited in an autosomal dominant pattern. That phrase means: a person needs only one copy of the changed gene to be at risk, and each child of a parent who carries the change has, on average, a 50% (one-in-two) chance of inheriting it. It does not skip predictably; each child’s chance is independent. Importantly, carrying the gene change does not always mean the disease will appear at a predictable age, and these are matters a genetic specialist can explain for your specific family.

Genetic counseling

A genetic counselor is a specially trained professional whose job is to help you understand the genetics, think through the options, and make decisions that are right for you — without pressure in any direction. They help families:

Understand what a specific PRNP result means.
Weigh whether and when to pursue testing.
Consider the impact on relatives, insurance, employment, and family planning.
Find emotional support and connect with others who understand.

The very personal decision of pre-symptomatic testing

For an adult relative who is well but knows the family carries a PRNP mutation, it is possible to be tested to learn whether they carry it too — this is called pre-symptomatic (or predictive) testing. This is one of the most personal decisions imaginable. Some people want to know in order to plan their lives, make decisions about family, or take part in research. Others choose not to know, which is an equally valid choice. There is no medicine yet that prevents the disease in carriers, which makes the decision purely personal rather than medically necessary.

There is no “right” choice — only your choice. Predictive testing for genetic prion disease is always done with genetic counseling, usually over more than one appointment, and never rushed. Whatever you decide — to test, to wait, or never to test — is legitimate. A good counselor will support you without judgment, and you can change your mind. Take all the time you need.

Fatal Familial Insomnia (FFI) is caused by a specific mutation called D178N in the PRNP gene, paired with a specific genetic letter (methionine, abbreviated M) at codon 129. It is one of the rarest diseases in medicine — fewer than 100 families worldwide are known to carry the mutation — and it presents quite differently from classic CJD.

How FFI begins: The name is literal but in one sense misleading. Sleep disturbance is the defining early symptom, but it is not ordinary insomnia that responds to sleeping pills. Normal sleep gradually disintegrates: the normal stages of sleep (light sleep, deep sleep, dream sleep) stop occurring in their usual patterns. The person may lie in bed for hours in a state that is neither full sleep nor full wakefulness, sometimes with movements or behaviors (like acting out dreams) that can be alarming to witness. Over weeks to months, the inability to fall or stay in true, restorative sleep becomes almost complete.

Autonomic symptoms (the body going out of regulation): In parallel with the sleep disruption, the autonomic nervous system — the part of the nervous system that runs the body’s automatic functions — begins to malfunction. This produces episodes of excessive sweating, a racing heart rate, high blood pressure, elevated body temperature, and later, inability to regulate body temperature normally. Weight loss is common. These autonomic symptoms can be striking and alarming, and they are relatively distinctive features that distinguish FFI from typical sCJD.

Cognitive and motor symptoms: As FFI advances, memory, attention, and other cognitive functions deteriorate. Hallucinations — typically vivid and disturbing — often develop. Motor problems (difficulty walking, tremor, unsteady gait) appear in the later stages. The terminal phase resembles that of other prion diseases, with akinetic mutism and ultimately death from complications.

Typical course: Median survival from the onset of clear symptoms is approximately 12–18 months, though variation across families and individuals is significant. Unlike sCJD, which kills most people within months, FFI families typically have somewhat more time, which both allows more planning and demands more sustained caregiving.

For at-risk family members: FFI follows autosomal dominant inheritance, meaning each biological child of an affected parent has a 50% chance of inheriting the D178N mutation. Pre-symptomatic genetic testing is available but should only be pursued within a formal genetic counseling program, given the profound psychological and practical implications. Because FFI carriers can be identified before symptoms appear, research programs — including those organized through the Prion Alliance (prionalliance.org) — are specifically recruiting at-risk individuals who have not yet developed symptoms, for natural-history studies that lay the groundwork for future prevention trials.

GSS is a very rare inherited prion disease caused most often by the P102L mutation in PRNP (and several other mutations), and it presents quite differently from typical CJD. It is sometimes described informally as “prion disease in slow motion.”

How GSS begins: The first signs are almost always cerebellar — meaning problems with balance, coordination, and walking. A person aware of their family’s GSS history may become hyperaware of any balance problem as potentially the first sign. For someone without that family context, the gait disturbance is often attributed for months or years to other conditions: vestibular problems, orthopedic issues, age-related balance decline, or even multiple sclerosis.

Disease course: Unlike sCJD, which kills most people within months, GSS typically unfolds over 2–10 years. This is a strikingly different time frame. The slower progression means more time for the person to maintain meaningful relationships, activities, and contributions to their family and community — a genuinely different experience from sCJD caregiving, even though the ultimate outcome is the same. Dementia develops later in the course, often well after the cerebellar symptoms are well established. Speech becomes progressively slower and harder to understand. The terminal phase, when it arrives, resembles that of other prion diseases.

What the brain looks like: GSS is characterized by distinctive multicentric plaques of misfolded prion protein scattered throughout the brain, detectable under the microscope at autopsy. These plaques are sometimes called “kuru plaques” because they resemble those seen in kuru, the prion disease that affected the Fore people of Papua New Guinea.

For family members: Like FFI, GSS follows autosomal dominant inheritance. Penetrance is high but not 100% — not every carrier of the P102L or other GSS mutations develops the disease, and the age of onset and rate of progression vary considerably even within the same family and mutation. This variability, while scientifically interesting, adds a layer of uncertainty that families often find deeply challenging to live with. Genetic counseling is essential before any decision about pre-symptomatic testing, particularly given the long potential incubation and the lack of any treatment to offer those who test positive.

Familial CJD caused by the E200K mutation — the most common inherited prion disease mutation worldwide — looks and behaves very similarly to sporadic CJD clinically. The person develops rapidly progressive dementia, myoclonus, ataxia, and typically dies within 4–8 months. From the outside, and even from most clinical tests, E200K familial CJD is nearly indistinguishable from sporadic CJD. The differences that matter most are the implications for the family:

Earlier onset: E200K familial CJD typically begins in the mid-to-late 50s rather than the late 60s of sporadic CJD — meaning working-age adults and often still-active grandparents are affected. The earlier onset changes the social and financial landscape of the illness.
Where E200K is more common: Historically higher rates of E200K familial CJD are found in specific populations: people of Libyan Jewish descent (and their relatives worldwide), in parts of Slovakia, and in Chile. Cases occur in people of all ethnic backgrounds, but the clustering in these groups has led to their being recognized as higher-risk communities with ongoing genetic counseling programs and research efforts. If someone in these communities develops rapidly progressive dementia, E200K testing should be strongly considered.
Penetrance: E200K has very high but not 100% penetrance — the majority of carriers develop the disease, but some appear to live full lifespans without symptoms. This incomplete penetrance makes the decision about pre-symptomatic testing in well relatives particularly complex: a positive test means a high but not certain risk, over an uncertain timeframe.
Other PRNP mutations: Many other mutations in the PRNP gene cause familial CJD with clinical courses broadly similar to sCJD, though each mutation has its own penetrance, age of onset, and sometimes specific clinical features. V210I, D178N-129V (which causes familial CJD rather than FFI), M232R, and others have all been described. A genetic counselor familiar with prion disease can help families understand what a specific mutation means for their family.
Research for at-risk individuals: Research programs specifically study and recruit PRNP mutation carriers who have not yet developed symptoms. The Prion Alliance (prionalliance.org) and the CJD Foundation (cjdfoundation.org) can connect families with these research opportunities, which are foundational for future prevention trials.

Questions to Ask Your Doctor — About Research & Genetics

Are there any clinical trials or research studies my loved one could realistically take part in right now?
Can you refer us to a specialist prion center that would know about current research?
Has any treatment ever been proven to slow CJD — and what should I make of things I read online?
Could this be a genetic form? If so, what does that mean for our family?
Can we meet with a genetic counselor, and what would PRNP testing involve?
For well relatives, what is involved in deciding about pre-symptomatic testing — and is there any rush?
Is there pre-symptomatic research that at-risk relatives might one day consider?
How can our family contribute to research or surveillance if we wish to?

Caregiver Guidance — For the People Holding It All Together

If you are the partner, child, parent, sibling, or friend caring for someone with CJD, this section is for you. The speed of this disease asks an enormous amount of caregivers in a very short time — physically, emotionally, and practically. Please know that taking care of yourself is not selfish; it is essential, both for you and for the person you love.

Pace yourself for a fast, intense journey

Because CJD often progresses in weeks to months, you may find yourself learning, deciding, and grieving all at once. It is normal to feel overwhelmed. Try, where you can, to accept help, to delegate, and to take things one day — sometimes one hour — at a time. You do not have to do everything, and you do not have to do it perfectly.

Build a circle of support early

Bring in palliative care and home-health/hospice support sooner rather than later. They lighten the load and bring expertise.
Lean on the CJD Foundation (HelpLine 800-659-1991). They offer family support, can connect you with others who truly understand, and know the disease intimately.
Accept practical help. When people ask “what can I do?”, have an answer ready — meals, errands, sitting with your loved one so you can rest, helping with paperwork.
Share the caregiving. No one person can — or should — do this alone around the clock.

Caring for your own heart

Anticipatory grief — grieving before the loss — is real and exhausting. So are guilt, anger, fear, and the strange guilt that can come with moments of relief or even peace. All of these feelings are normal. Consider talking with a counselor, chaplain, social worker, or support group. Protect your sleep when you can, eat something, step outside. You matter too.

Practical day-to-day tips

Keep a simple notebook or phone note of symptoms, medicines, and questions for the team — the days blur, and this helps you advocate.
Make the environment safe and calm — reduce fall hazards early; later, soft lighting and familiar sounds.
Use familiarity as comfort — favorite music, well-loved blankets, photos, scents, the family pet.
Talk and touch even when there is no response. Hearing and the comfort of touch often persist; your presence reaches them.
Ask the team to teach you safe transferring, repositioning, and mouth care — small skills that prevent discomfort and injury.

For children and grandchildren. Children sense when something is wrong. Honest, age-appropriate words — and reassurance that they did not cause it and cannot catch it — help more than silence. A social worker or your hospice team can guide you, and the CJD Foundation has resources for families with children.

Transmission & Infection Control — What’s Safe (and What Families Worry About)

You can care for your loved one safely.
CJD is not spread by hugging, kissing, holding hands, sharing food or drink, coughing, sneezing, or any of the ordinary contact of daily caregiving. You will not catch it by loving and caring for your family member. Ordinary, sensible hygiene — the kind you would use caring for anyone — is all that is needed at home.

This is one of the most common and important fears families carry, often silently, so let us address it clearly and reassuringly. Prion disease is transmissible only under very specific circumstances that essentially never arise in everyday life. The misfolded prion is found mainly in the brain, spinal cord, and certain nervous-system tissues — not in the air you share, the food you eat together, or a kiss goodnight.

Everyday contact — safe

Hugging, kissing, holding hands, comforting touch.
Sharing meals, utensils, cups, and bathrooms.
Helping with washing, dressing, feeding, and personal care using ordinary hygiene.
Being in the same room, talking, sleeping nearby.

Where special precautions do apply

Special precautions are needed only in particular medical and surgical situations, because the prion is unusually tough and resists ordinary sterilization. These are handled by professionals, not families:

Surgery and procedures involving brain or spinal-cord tissue — hospitals use special instrument-handling and (where required) single-use instruments.
Lumbar puncture and certain neurological procedures — routine safe handling of samples.
Autopsy and tissue handling — performed by trained pathologists with appropriate precautions.

Blood and organ donation

People with CJD (and, in many countries, people who carry a genetic risk or who lived in certain regions during the BSE era) generally cannot donate blood or organs, as a precaution. This is standard policy and not a reflection on your loved one; it is simply part of the careful safeguards that have made transmission so rare.

If you have a specific concern — for example about a recent shared medical procedure, a needlestick, or care at home — ask the medical team or call the CJD Foundation HelpLine (800-659-1991). They can give you clear, calm, accurate answers tailored to your situation.

Advance Care Planning

Because CJD can progress quickly and affects the ability to communicate early, planning ahead is an act of love — it lets your loved one’s wishes guide their care, and it spares the family agonizing guesswork later. Where possible, have these conversations and put documents in place sooner rather than later.

Advance directive / living will — a written statement of the person’s wishes about treatments such as resuscitation, hospital transfers, feeding tubes, and where they wish to be cared for.
Health care proxy / durable power of attorney for health care — naming a trusted person to make medical decisions once your loved one cannot.
Power of attorney for finances — so bills, benefits, and affairs can be managed.
Goals-of-care conversation — with the medical and palliative teams, clarifying that the focus is comfort and dignity, and what that means in practice (for example, a plan to avoid distressing hospital transfers and to treat symptoms at home where possible).
Preferences about autopsy and brain donation — discussed gently and in advance where possible (see below), as arrangements are easier when planned ahead.

Understanding what hospice provides — and when to ask for it

Many families hesitate to pursue hospice because they worry it means “giving up,” that it will hasten death, or that they will lose access to medical care. None of these concerns is accurate:

Hospice does not hasten death — research consistently shows that hospice enrollment is associated with equal or slightly longer survival compared to conventional care in terminal illness, because symptom management is optimized and people are not subjected to distressing interventions without meaningful benefit.
Hospice provides more care, not less — in the US, the Medicare hospice benefit typically provides registered nursing visits multiple times per week, home health aide support for bathing and personal care, medical equipment (hospital bed, wheelchair, oxygen, pressure-relief mattress), social worker visits, chaplain and spiritual care, medications for symptom control related to the terminal diagnosis, and bereavement counseling for the family after death — all at little or no out-of-pocket cost for Medicare beneficiaries. Most private insurance plans follow Medicare’s hospice model.
Eligibility: Hospice in the US requires a physician’s certification that, if the illness follows its expected course, the person is expected to live six months or fewer. For CJD, where the prognosis is clear and uniformly fatal, this certification is almost never in question. The certification can be renewed indefinitely if the person lives longer than anticipated.
You can leave hospice: If someone enrolled in hospice decides to pursue curative treatment, they can disenroll at any time and re-enroll when appropriate. For sporadic CJD, where no curative treatment exists, this provision is rarely relevant, but it is worth knowing that hospice is not an irreversible choice.
The right time to ask: Most families, in hindsight, wish they had enrolled in hospice sooner rather than later. The CJD Foundation and specialist prion teams routinely recommend asking about hospice referral at or shortly after diagnosis, not waiting until the person is clearly in the final days. Earlier enrollment means more time to build relationships with the hospice team and to benefit from the full range of supports they offer.

A social worker, palliative care team, or hospice can walk you through the paperwork specific to your country or state, and can help ensure documents are completed correctly and shared with everyone who needs them.

Autopsy, Surveillance & the NPDPSC — Why It Helps Families and Research

Considering an autopsy is painful, and no family should feel pressured. But many families find real value and even comfort in it, for reasons worth understanding gently.

Why families choose autopsy

Certainty. Examining brain tissue is the only way to confirm prion disease definitively and to identify the exact type. For some families, knowing for certain brings a measure of peace.
Answers for relatives. Confirming whether the disease was sporadic or genetic has direct implications for other family members — clarity that can guide them and their own children.
Contribution to research and surveillance. Nearly everything science knows about prion disease has come from families who allowed examination and donated tissue. It is a profound and lasting gift to others.

The National Prion Disease Pathology Surveillance Center (NPDPSC)

In the United States, the National Prion Disease Pathology Surveillance Center (NPDPSC), based at Case Western Reserve University in Cleveland, Ohio, is the central resource for prion-disease diagnosis and surveillance. It performs RT-QuIC testing and neuropathology (autopsy) examination at no charge to families, provides definitive diagnosis, and tracks cases nationally. Your medical team, hospice, or the CJD Foundation can help arrange testing and, if you choose, autopsy through the NPDPSC. Other countries have their own national CJD surveillance units that play a similar role (see the international section).

If you are considering it, plan early. Autopsy and brain-donation arrangements are far smoother when discussed in advance with the care team, hospice, and the surveillance center — ideally before the final days. The CJD Foundation (800-659-1991) can guide families through the practical steps with compassion.

class="content-section" data-stage="resources">

Specialty Centers & Support Directory

You do not have to navigate this alone. Below are centers and organizations that specialize in prion disease, rapidly progressive dementia, and family support. Phone numbers are provided where we are confident of them; otherwise we give the name and location so you can find current contact details.

University of Utah — Clinical Neurosciences Center (Salt Lake City) — behavioral neurology and cognitive/dementia evaluation, including rapidly progressive dementia work-up and referral.
ARUP Laboratories (Salt Lake City) — national reference laboratory; can perform PRNP genetic testing ordered through your physician.
George E. Wahlen VA Medical Center (Salt Lake City) — for eligible veterans; neurology and palliative care services. Phone: 801-582-1565.
Intermountain Health (Utah region) — neurology, palliative care, and home-health/hospice services across the region.

National Prion Disease Pathology Surveillance Center (NPDPSC) — Case Western Reserve University, Cleveland, Ohio — the US national center for prion-disease diagnosis; performs free RT-QuIC testing and neuropathology/autopsy examination, and conducts national surveillance.
UCSF Memory and Aging Center (San Francisco, California) — a leading center for rapidly progressive dementia and prion disease evaluation, research, and second opinions.
CJD Foundation — the national patient and family support organization for all forms of prion disease. HelpLine: 800-659-1991. Offers family support, information, connection to others, guidance on testing and autopsy, and a research focus.

Public Health Agency of Canada — CJD Surveillance System — Canada’s national surveillance program for prion disease, providing diagnostic support, surveillance, and information for families and clinicians.

National CJD Research & Surveillance Unit (NCJDRSU) — Edinburgh, United Kingdom — the UK’s national surveillance and research unit for CJD and other prion diseases.
National Prion Clinic / MRC Prion Unit at UCL — London, United Kingdom — a specialist NHS clinic and research center caring for people with prion disease and their families, and a hub for prion research.
French National Reference Centre for Prion Diseases (CNR-Maladies à Prions) — Hôpital Lariboisière / Pitié-Salpêtrière, Paris, France — France’s national reference and surveillance center for prion diseases; coordinates diagnosis and research and participates in EuroCJD. France was the site of the landmark randomized doxycycline trial (Haïk et al., Lancet Neurology 2014).
German National Reference Centre for TSE / NRZ Spongiforme Enzephalopathien — University Medical Centre Göttingen, Germany — one of the world’s leading prion research centers and a key EuroCJD participant. The Göttingen group (including internationally recognized researchers in prion disease) has contributed fundamental work on molecular subtypes, RT-QuIC optimization, and novel biomarkers.
Istituto Superiore di Sanità (ISS) — Rome, Italy and reference centers at the University of Bologna — Italy’s national surveillance structure for prion diseases; EuroCJD participant.
Australian National CJD Registry (ANCJDR) — University of Melbourne, Melbourne, Australia — national surveillance and reference testing for prion disease across Australia and the Asia-Pacific region; accepts referrals from throughout the region.
Johns Hopkins Department of Neurology — Baltimore, Maryland, USA — academic referral center with expertise in rapidly progressive dementias and prion disease evaluation in complex cases.
Columbia University Irving Medical Center / Cognitive Neuroscience Division — New York, NY, USA — academic referral center for prion disease and rapidly progressive dementia.
Mayo Clinic — Rochester, Minnesota; Phoenix, Arizona; Jacksonville, Florida, USA — extensive rapidly progressive dementia program across multiple campuses; nationwide referral center. Rochester: 507-284-2511.

Many other countries maintain national CJD surveillance units and specialist neurology centers. Your local neurologist, or the CJD Foundation, can help you identify the nearest specialist resource.

International Access & Surveillance

Prion disease is recognized and monitored worldwide, and many countries operate dedicated national CJD surveillance units that confirm diagnoses, track cases, and support families — often free of charge. Because there is no approved treatment anywhere, the international picture is less about access to drugs and more about access to accurate diagnosis, expert advice, surveillance, and compassionate care, which are broadly available through national health systems and specialist centers.

United States — the NPDPSC (Cleveland, Ohio) provides free RT-QuIC and neuropathology; the CDC also conducts national surveillance.
United Kingdom — the National CJD Research & Surveillance Unit (Edinburgh) and the National Prion Clinic / MRC Prion Unit at UCL (London) provide surveillance, specialist NHS care, and research.
Canada — the Public Health Agency of Canada’s CJD Surveillance System.
United Kingdom — the National CJD Research & Surveillance Unit (NCJDRSU) at the University of Edinburgh is one of the world’s oldest and most authoritative CJD surveillance units; it coordinated the identification and characterization of vCJD during the BSE crisis. The National Prion Clinic at the National Hospital for Neurology and Neurosurgery (UCL, London) provides specialist clinical care and access to research programs for families across the UK and internationally. The UK has implemented uniquely comprehensive blood-safety measures (universal leukodepletion of all blood products, importation of plasma from non-BSE-risk countries) in response to the vCJD epidemic.
Germany — the National Reference Centre for TSE (NRZ Spongiforme Enzephalopathien) at the University Medical Centre Göttingen is a globally recognized research and surveillance institution, with foundational contributions to RT-QuIC methodology and molecular subtype characterization. Germany participates in the EuroCJD network and operates national surveillance for prion diseases.
France — the National Reference Centre for Prion Diseases (CNR-Maladies à Prions) coordinates diagnosis and surveillance; France was the site of the definitive randomized controlled trial of doxycycline in sporadic CJD (published 2014), the most rigorous therapeutic trial ever conducted in this disease.
Japan — Japan operates a national CJD surveillance system under the Ministry of Health, Labour and Welfare. Japan has particular historical significance for iatrogenic CJD from dura mater grafts (Lyodura — a cadaveric dural graft product used in neurosurgery) — Japan documented the world’s largest cluster of medically transmitted CJD cases, which prompted critical global policy changes in how cadaveric surgical tissue products are used and regulated.
Canada — the CJD Surveillance System operated by the Public Health Agency of Canada (PHAC) tracks prion disease cases nationally. For specialist clinical support, the Toronto Western Hospital / Krembil Brain Institute and other academic neurology centers serve as referral destinations for complex prion disease cases.
Australia — the Australian National CJD Registry (ANCJDR) at the University of Melbourne serves as Australia’s national surveillance and reference center, accepting referrals from across the Asia-Pacific region and conducting active diagnostic support.
Israel — Israel has a historically higher rate of E200K familial CJD among communities of Libyan Jewish descent; this well-characterized population has contributed significantly to the understanding of inherited prion disease, including penetrance data and age-of-onset distributions.
Europe & beyond — virtually all European countries maintain CJD surveillance through the EuroCJD collaborative network, which coordinates case definitions, data collection, and reporting across member states. South Korea, Brazil, Argentina, and other countries operate national prion surveillance systems aligned with WHO guidance. No country has an approved disease-modifying treatment for prion disease, but international collaboration on biomarkers, trial design, and surveillance is active and well-coordinated.

The diagnostic standards described in this guide — MRI with DWI, RT-QuIC, supportive spinal-fluid markers, and PRNP genetic testing — are used internationally and are reflected in widely adopted diagnostic criteria. If you are outside the US, ask your neurologist about your country’s national CJD surveillance unit; they are an excellent source of expertise, confirmation, and family support.

Investigational prion-lowering therapies (ASOs) are not approved for routine use in any country. Be wary of any clinic, in any nation, that offers paid “prion treatments” or cures — legitimate research is conducted through established academic prion centers and ethics-approved studies, not commercial offerings.

Financial & Practical Resources

A fast-moving illness brings sudden practical and financial pressures — time off work, equipment, home help, care costs. You do not have to figure this out alone; help exists, and a social worker is your best guide to what applies where you live.

Ask for a medical social worker — available through hospitals, palliative care, and hospice. They are experts at connecting families to benefits, services, and equipment quickly.
Hospice and palliative benefits — in the US, the Medicare hospice benefit covers comfort-focused care, medicines, equipment, and support; many countries provide community palliative and hospice care through the health system or charitable hospices at no or low cost.
Disability and family-leave support — depending on your country and situation, there may be disability benefits, caregiver leave, or financial assistance available; a social worker can identify what fits.
Home equipment — hospital beds, pressure-relieving mattresses, wheelchairs, lifts, and other equipment can often be arranged through home-health, hospice, or charitable loan programs.
The CJD Foundation (800-659-1991) — can point families to practical resources and connect you with others who have navigated the same path.
Legal and estate paperwork — addressing powers of attorney and affairs early reduces stress later; a social worker or legal-aid service can help.

The rapid course of CJD means families face sudden, urgent financial decisions at the same time they are in emotional crisis. Knowing what is available before you desperately need it can prevent scrambling at the worst possible moment.

Social Security Disability and Compassionate Allowances: In the United States, CJD qualifies under Social Security’s Compassionate Allowances program, which fast-tracks disability benefit applications for people with clearly severe and well-established conditions. Without Compassionate Allowances, Social Security Disability Insurance (SSDI) typically involves a 3–5 month processing delay followed by a 24-month Medicare waiting period — both far too long for most CJD patients. With Compassionate Allowances, processing is significantly accelerated. Apply immediately upon diagnosis, and make explicit on the application that CJD is the diagnosis.

Medicare hospice benefit: If the person already has Medicare and is certified by a physician as likely to live six months or fewer, the Medicare hospice benefit provides comprehensive comfort-focused care at home or in a hospice facility, covering nursing visits, aide support, medications for symptom control, medical equipment (hospital bed, wheelchair, oxygen), and bereavement support for the family — with little to no out-of-pocket cost. The hospice benefit does not prevent the person from receiving medical care for other conditions; only care related to the terminal diagnosis shifts to hospice management. Enrolling in hospice is not “giving up” — it is redirecting resources toward what will most help.

Medicaid: For those without Medicare, Medicaid can cover long-term care, home health services, and hospice, with eligibility and scope varying significantly by state. Medical social workers at the hospital or through the palliative care team can help navigate Medicaid eligibility and application quickly.

Family and Medical Leave Act (FMLA): In the US, eligible employees at companies with 50 or more employees can take up to 12 weeks of unpaid, job-protected leave per year to care for a seriously ill family member (spouse, child, or parent). This leave can be taken all at once or intermittently (a few hours here, a day there, as needed). Notify your employer’s HR department as early as possible — the paperwork takes time, and starting the process early prevents gaps in job protection when you most need flexibility.

Short-term disability and paid family leave: Many employers offer short-term disability plans that provide partial income replacement during medical leave. Some US states (California, New York, New Jersey, Washington, Massachusetts, Connecticut, Oregon, Colorado, and others) have mandated paid family leave programs that provide partial wage replacement for eligible workers caring for seriously ill family members. Check your state’s labor department website or ask your HR representative.

Area Agency on Aging and community supports: Every US county is served by an Area Agency on Aging (find yours at eldercare.acl.gov or by calling the Eldercare Locator: 1-800-677-1116). These agencies can connect families with in-home services (personal care aides, homemaker services), meal delivery, transportation, caregiver respite programs, and other practical supports — many available at no cost or on a sliding scale based on income. These services can extend a family’s capacity to care for their loved one at home.

Durable power of attorney — act quickly: One of the most important practical steps in the first days after a CJD diagnosis is ensuring that legal documents are in place: a durable power of attorney for finances (allowing someone to manage bank accounts, pay bills, and make financial decisions) and a health care power of attorney (allowing someone to make medical decisions). Once cognitive decline is significant enough that the person can no longer legally sign documents, gaining this authority becomes much more difficult, time-consuming, and expensive. An elder-law attorney can establish these documents quickly; many hospice programs include a social worker who can provide guidance at no cost about which documents are needed and how to access legal help affordably.

Making end-of-life practical arrangements while the person with CJD is still well enough to be involved, or at least while the family has enough emotional bandwidth to think clearly, reduces both cost and emotional burden significantly.

Funeral and burial arrangements: Arranging in advance — whether burial, cremation, or something else — allows the family to make considered decisions rather than ones driven by grief and urgency. Pre-arranging also typically locks in lower prices. Many funeral homes and hospice social workers can facilitate advance planning conversations. Because CJD involves prion disease, it is worth informing the funeral home in advance so they can plan appropriately; the CDC and WHO have published guidance for funeral homes on handling remains from prion disease patients safely. Standard embalming and cremation procedures are manageable with appropriate precautions, and most funeral homes are familiar with these guidelines.

Brain donation through the NPDPSC: If the family is considering contributing to prion disease research through brain donation, arrangements must be made before death — ideally weeks in advance — because the brain tissue must be collected within hours of death for the tissue to be usable for research and definitive diagnosis. The NPDPSC (National Prion Disease Pathology Surveillance Center) at Case Western Reserve University covers the associated costs and provides the family with a definitive neuropathological diagnosis within months, which many families find deeply meaningful. The NPDPSC staff is experienced and compassionate in working with families through this process. Call them at 216-368-0587 to begin the conversation early.

Estate and financial affairs: Addressing powers of attorney (above), updating beneficiaries on accounts and life insurance policies, and reviewing any outstanding debts or financial obligations early reduces stress later. A financial planner or elder-law attorney can provide a checklist review in a single consultation. If the person with CJD was the primary income earner, understanding what survivor benefits exist — through Social Security, pension, life insurance, or employer programs — should happen early enough to plan for the family’s financial future.

The CJD caregiving period is intense, compressed, and in many ways traumatic. When the person dies, the combination of profound relief (that suffering is over), deep grief, and the physical exhaustion of the caregiving period can leave family members depleted in ways they didn’t anticipate and that are hard to explain to people who weren’t there.

What makes CJD grief different: Post-CJD bereavement has several features that distinguish it from many other kinds of loss. The death came with extraordinary speed — most families had weeks, not years, from the first concern to the final goodbye. The person may have stopped being recognizable as themselves weeks before their body died, creating a kind of “double loss” that can leave families grieving someone who has already been gone for a while by the time death arrives. The rarity of the diagnosis means that well-meaning grief counselors and support groups have almost never encountered CJD before, and families may feel deeply alone in the specific nature of their experience.

CJD-specific peer support: The CJD Foundation offers bereavement support that connects families with trained volunteer supporters who have personal experience with CJD loss — people who understand the diagnosis, the speed, the particular kinds of decisions families had to make, and the unusual aspects of caring for someone with prion disease. This peer connection is often more healing than generic grief support. Contact the Foundation’s HelpLine at 800-659-1991.

Professional mental health support: Grief counseling with a therapist who specializes in traumatic, sudden, or complicated grief can be very helpful after a prion disease loss. If you are experiencing severe depression, significant anxiety, intrusive memories or images of the caregiving period, or difficulty functioning weeks after the death, these are appropriate to discuss with a mental health professional. These are normal responses to an extraordinary experience and do not indicate weakness.

For children and teenagers in the family: Children who witnessed a grandparent’s, parent’s, or sibling’s CJD illness carry those memories with them. Age-appropriate support — through school counselors, pediatric psychologists, or children’s grief programs offered by many children’s hospitals and hospice organizations — can help children process an experience that most adults around them have never encountered before. Not talking about what happened often increases rather than decreases children’s anxiety and confusion.

Do not hesitate to ask for help with money and logistics. Reaching out is not a burden — these supports exist precisely for families facing exactly what you are facing, and using them frees you to focus on what matters most.

An Honest Conversation About Hope

We have been honest with you throughout this guide, and we will be honest now: CJD will take your loved one, and likely sooner than seems bearable. Pretending otherwise would not be kindness. But honesty about the prognosis does not mean there is no hope — it means we are honest about where hope can truly live.

Hope, here, is not hope for a cure that does not exist. It is something quieter and, in its own way, sturdier:

Hope for comfort — that the symptoms will be controlled and your loved one will not suffer needlessly. This hope is realistic; good palliative care delivers it.
Hope for dignity — that your loved one will be treated with tenderness and respect to the very end, surrounded by the people and things they love.
Hope for presence — that even as words fade, connection remains; that a held hand, a familiar song, a beloved voice still matter, because they do.
Hope for meaning — that the love you give now, and any choice you make to contribute to surveillance or research, ripples outward to other families.
Hope for the future — that the science aimed at the root of this disease, much of it driven by affected families, will one day spare others what you are living through now.

And there is hope for you — that you will come through this changed but whole, carrying your love forward. Grief is the price of love, and your grief is a measure of how deeply you have loved. Be gentle with yourself. Accept help. Rest when you can. Reach out to the CJD Foundation and others who understand. You are doing one of the hardest and most loving things a person can do, and you are not doing it alone.

If you take one thing from this section: caring for someone with CJD is not a failure to cure — it is a profound act of love, presence, and dignity. That love is never wasted, and it is never forgotten.

Reproductive Considerations & CJD

Creutzfeldt-Jakob disease almost exclusively affects adults over 60 years of age (sporadic CJD) or follows decades of incubation (variant CJD). Pregnancy concurrent with CJD is essentially unknown in medical literature and is not a recognized clinical scenario.

For family members of reproductive age

Transmission risk to family members: CJD is NOT transmitted through normal caregiving contact (touching, hugging, breathing). Standard caregiving, including by pregnant family members, poses no known risk of prion transmission.
Genetic CJD (gCJD) — a minority of CJD cases are caused by mutations in the PRNP gene (familial CJD). Family members of people with confirmed gCJD who are of reproductive age may wish to consider genetic counseling to understand their own risk and options including predictive testing and, if they are gene carriers, preimplantation genetic testing.

If you are a caregiver for someone with CJD and are pregnant: standard caregiving is safe. Follow standard infection control precautions when handling blood or body fluids (gloves for wound care). Ask the care team if you have specific concerns.

Frequently Asked Questions

These are the questions families most often carry — sometimes unable to ask them aloud. We answer them directly.

This is one of the most common and most painful questions, and it deserves a direct answer. Modern diagnostic criteria, combined with brain DWI-MRI, CSF RT-QuIC, and expert clinical review, establish a “probable” CJD diagnosis with very high confidence — typically 95–98% in patients evaluated at specialist centers with all modern tools. A “definite” diagnosis still requires brain tissue examination at autopsy, which is why it matters to many families.

Asking your doctor “How certain is this diagnosis, and what would change the picture?” is entirely appropriate. If you have specific concerns — whether an autoimmune encephalitis antibody panel was sent, whether RT-QuIC was performed, whether the MRI was read by someone familiar with CJD patterns — raise them. Seeking a second opinion from a specialist prion center is reasonable and usually strengthens families’ confidence in either direction.

This is often the question families carry most heavily, and the honest answer is nuanced. In the middle stages of CJD, when the person is confused or agitated, there is genuine uncertainty about their subjective experience. They may feel frightened by what is happening even when they cannot articulate it. Good palliative care actively manages this possibility — treating agitation, reducing distressing stimulation, using medications to relieve distress when needed.

In akinetic mutism (the late stage), neurological evidence suggests that conscious experience as we typically understand it is significantly diminished, though the ability to sense familiar voices, music, and touch at some level may persist. Pain in the late stage is assessed using observational behavioral tools rather than waiting for the person to report it — staff watch for facial grimacing, limb tension, changes in heart rate and breathing. If you are worried your loved one is in pain, say so explicitly to the care team and ask what assessment tools they are using and what medications are available.

We understand the impulse to search for anything. It would not be love if you did not. We owe you honesty: as of the time this guide was written, no experimental treatment has shown meaningful benefit in established sporadic CJD in a controlled study. The trials that have been conducted — quinacrine, doxycycline, pentosan polysulfate, flupirtine — were all negative.

The most scientifically promising direction is prion-lowering therapy using antisense oligonucleotides (ASOs). These are in early-stage research for genetic prion disease, tested in people who carry a mutation but have not yet developed symptoms. This does not yet translate to available treatment for someone with established sporadic CJD — the disease progresses too quickly for the current version of these approaches to act.

If someone offers an “experimental treatment” outside of a formal research program — particularly for a fee — this is almost certainly not legitimate science. The CJD Foundation and specialist prion centers can evaluate any specific claims you encounter. The most reliable ways to honor your loved one now, and to contribute to future families not facing this, are excellent comfort care and, if you choose, brain donation through the NPDPSC.

The answer depends on which form of CJD your family member has. Ask your doctor: “Is there any evidence this could be a genetic or inherited form of CJD?”

Sporadic CJD (about 85% of cases): No genetic risk to family members. It occurs by what appears to be a spontaneous misfolding of the prion protein. Your children are not at higher risk than the general population, and you did not give it to anyone.

Genetic (familial) prion disease (about 10–15% of cases): If your family member’s CJD is confirmed to be caused by a PRNP mutation, then biological first-degree relatives have a 50% chance of having inherited the same mutation. This does not mean they will definitely develop the disease — penetrance is high but not 100% — but genetic counseling and the option of pre-symptomatic testing are appropriate to discuss.

Transmission in ordinary life: CJD is not transmitted through ordinary human contact. You cannot give it to a caregiver, visitor, or family member through touching, sharing food, or living together. The rare historical cases of transmission occurred through specific medical procedures — contaminated surgical instruments, cadaveric growth hormone preparations before 1985, a handful of corneal graft cases — entirely separate from ordinary caregiving and family life.

Children sense when something serious is happening, even when adults try to shield them. In most cases, honest and age-appropriate explanations reduce anxiety more than protective silence.

For young children (roughly ages 4–8): Simple, concrete language is most helpful. Something like: “Grandma’s brain is very sick. The doctors cannot fix it. We are making sure she is comfortable. She is going to die because of this illness, and that makes us very sad. It is not catching — you cannot get sick from holding her hand or being in the same room.” Children at this age need reassurance that they are safe, that they did not cause this, and that they can still visit and show love.

For older children and teenagers: More detail is appropriate. Many teenagers will search online once they hear the word “prion” and benefit from having a trusted adult guide their understanding rather than encountering alarming content alone. Answer honestly and at the level they are asking at. Acknowledge the difficulty: “This is one of the hardest things our family has been through, and it is okay to feel angry and sad and confused.”

School support: Inform the child’s school counselor confidentially so teachers can watch for signs of distress. Many children’s hospice programs offer grief support specifically for children living through a family member’s terminal illness — not just after the death but during it.

Glossary — Plain-Language Definitions

Prion: A normal brain protein that has folded into the wrong shape. The misfolded protein can force normal proteins to misfold too, in a chain reaction that damages the brain. Prion disease is caused by this process — not by any virus or bacterium.
PrP / prion protein: The everyday name for the protein involved. In its normal shape it is harmless; in its misfolded shape it causes disease.
RT-QuIC: Real-time quaking-induced conversion — a highly accurate spinal-fluid test that detects abnormal prion protein, now the most important test for diagnosing CJD during life.
Myoclonus: Sudden, brief, involuntary muscle jerks. A hallmark symptom of CJD; usually treatable with comfort medicines.
Ataxia: Loss of balance and coordination, causing an unsteady walk, clumsiness, and falls.
Akinetic mutism: A late stage in which the person can no longer move purposefully (akinetic) or speak (mutism), although they may still have periods of wakefulness.
DWI-MRI (diffusion-weighted imaging): A type of brain MRI scan that can reveal patterns characteristic of CJD and is central to modern diagnosis.
PRNP: The gene that carries the instructions for making the prion protein. Inherited changes in this gene cause genetic prion disease.
Sporadic CJD: The most common form (about 85% of cases), occurring with no known cause; not inherited and not contagious in everyday life.
Genetic (familial) prion disease: An inherited form caused by a change in the PRNP gene; includes Fatal Familial Insomnia and Gerstmann-Sträussler-Scheinker syndrome.
Iatrogenic CJD: CJD inadvertently transmitted in the past through certain medical procedures; now very rare due to modern safeguards.
Variant CJD (vCJD): A rare form linked to eating beef from cattle with “mad cow disease”; mostly seen in the UK in the 1990s–2000s, now extremely rare.
BSE (bovine spongiform encephalopathy): The prion disease of cattle, known popularly as “mad cow disease,” historically linked to variant CJD in people.
Palliative care: Specialized medical care focused on relieving symptoms and improving quality of life for people with serious illness, at any stage, alongside other care.
Hospice: Comfort-focused care for people nearing the end of life, usually provided where the person lives, supporting both patient and family.
Codon 129: A specific position (numbered 129) on the PRNP gene where the genetic letter can be M (methionine) or V (valine), inherited independently from each parent. Whether a person has MM, MV, or VV at this position influences which form of sporadic CJD they may develop and how rapidly it progresses — and whether the D178N mutation causes Fatal Familial Insomnia (MM) versus familial CJD (VV or MV).
Fatal Familial Insomnia (FFI): A rare inherited prion disease caused by the D178N mutation in PRNP paired with methionine at codon 129. Progressive, eventually total inability to sleep is the hallmark symptom, along with autonomic dysfunction (sweating, racing heart, high blood pressure). Fewer than 100 families worldwide are known carriers.
Gerstmann-Sträussler-Scheinker Syndrome (GSS): An inherited prion disease most often caused by the P102L mutation in PRNP. It begins with cerebellar ataxia (balance and coordination problems) and develops dementia later, with a course of 2–10 years — much slower than sporadic CJD.
PrP^C (cellular prion protein): The normal, correctly folded form of the prion protein found in healthy brain cells. It is harmless in its normal shape. When PrP^C misfolds into PrP^Sc, disease results.
PrP^Sc (scrapie prion protein): The abnormally shaped, disease-causing form of the prion protein. The “Sc” comes from scrapie, the prion disease of sheep. PrP^Sc is resistant to most sterilization methods and can trigger nearby normal prion proteins to misfold — this self-propagating property is what makes prion disease unique.
Spongiform encephalopathy: The microscopic appearance of brain tissue in prion disease: as neurons die and are replaced by tiny round holes (vacuoles), the tissue develops a sponge-like (spongiform) appearance visible only under a microscope at autopsy.
Seed amplification assay (SAA): The family of tests — including RT-QuIC — that detect very small amounts of misfolded prion protein by using a tiny amount as a “seed” to trigger a rapid chain reaction in a test tube, amplifying the signal until it is detectable. This approach is far more sensitive than older techniques.
Olfactory mucosal brushing: A minimally invasive technique for collecting cells from the upper nasal passage (close to the brain) to test for RT-QuIC. A small brush is inserted through the nostril to the olfactory area. It achieves sensitivity and specificity comparable to CSF RT-QuIC without requiring a lumbar puncture.
Cortical ribboning: A distinctive pattern on brain DWI-MRI in which the surface cortex of the brain shows a ribbon-like pattern of restricted water diffusion, reflecting rapid neuron death. It is one of the most characteristic and diagnostically helpful MRI findings in CJD.
Periodic sharp-wave complex (PSWC): A characteristic brain-wave pattern seen on EEG (brain wave test) in CJD: large, sharp electrical waves that repeat at regular intervals (roughly once per second). Most common in the classic MM1 form of sporadic CJD; less consistent or absent in other subtypes and in vCJD.
14-3-3 protein: A protein found in many body tissues; when detected in spinal fluid (CSF), elevated levels indicate rapid, significant neuron death. Used as a supportive marker for CJD but not specific to prion disease — it is also elevated after stroke, encephalitis, and other conditions causing rapid brain injury.
Total tau protein (t-tau): A protein released from injured neurons into the spinal fluid. In CJD, total tau is often dramatically elevated — sometimes 10–100 times higher than in most other neurological diseases — reflecting the extraordinary speed of neuronal loss. Supports but does not confirm a CJD diagnosis.
Lumbar puncture (spinal tap): A procedure in which a needle is inserted between vertebrae in the lower back to collect a small amount of cerebrospinal fluid (CSF). RT-QuIC, 14-3-3, and tau are all measured on CSF. The procedure is done under local anesthesia; a temporary headache afterward is the most common side effect and usually resolves within 24–48 hours.
Autosomal dominant inheritance: An inheritance pattern where having just one faulty copy of a gene (from either parent) is sufficient to cause the disease or a high risk of it. Each child of an affected parent has a 50% chance of inheriting the mutated gene. All major genetic prion diseases (FFI, GSS, familial CJD) follow this pattern.
Penetrance: The proportion of people who carry a particular gene mutation who actually develop the associated disease. “High penetrance” means most carriers develop the condition; “incomplete penetrance” means some live full lives without symptoms. Most PRNP mutations have high but not 100% penetrance.
NPDPSC (National Prion Disease Pathology Surveillance Center): The US federal reference center for prion disease, at Case Western Reserve University in Cleveland, Ohio. Provides free RT-QuIC testing on CSF samples and free neuropathological confirmation at autopsy for suspected CJD cases. Phone: 216-368-0587.
Aspiration pneumonia: A lung infection caused by food, liquid, or secretions entering the lungs rather than the stomach. The most common direct cause of death in advanced CJD, as progressive difficulty swallowing (dysphagia) allows material to travel into the lungs.
Dysphagia: Difficulty swallowing, which commonly develops in the middle and late stages of CJD as neurological control of the swallowing mechanism deteriorates. Increases aspiration risk and requires careful management of food texture, thickened liquids, and eating position.
Clonazepam: A benzodiazepine medication (anti-anxiety/anti-seizure drug) commonly used in CJD to manage myoclonus. It is often the most effective first medicine tried for prion-associated muscle jerks. Titrated from a low starting dose to minimize sedation.
Levetiracetam: An anti-seizure medication also used for myoclonus management in CJD, sometimes combined with clonazepam. It has few significant drug interactions, which is helpful when someone is taking multiple comfort medications.
Kuru: A prion disease that affected the Fore people of Papua New Guinea, transmitted through ritual mortuary practices involving deceased individuals. Its discovery in the 1950s by Daniel Carleton Gajdusek established that a human brain disease could be caused by an infectious transmissible agent without a conventional virus or bacterium, laying the groundwork for our understanding of all prion diseases. Kuru is now extinct.
Advance directive / living will: A legal document in which a person writes their wishes for medical treatment if they later cannot communicate them. In CJD, creating an advance directive early — shortly after diagnosis and before significant cognitive decline — ensures the person’s own voice guides critical decisions about resuscitation, feeding tubes, and other interventions.
POLST / MOLST: Physician Orders for Life-Sustaining Treatment (POLST) or Medical Orders for Life-Sustaining Treatment (MOLST) — a medical order signed by a physician specifying which emergency interventions are wanted or not wanted. Unlike an advance directive, a POLST is a standing medical order that emergency responders and hospitals are legally required to follow. Particularly important for CJD patients as the disease progresses toward the final phase.
Social Security Compassionate Allowances: A Social Security Administration program that fast-tracks disability benefit applications for people with conditions that are clearly severe and well-established, including CJD. Significantly reduces the processing time compared with the standard disability application process. Apply immediately upon diagnosis and explicitly note CJD on the application.
Prion Alliance: A nonprofit organization (prionalliance.org) founded by two genetic prion disease patients — one carrying E200K familial CJD, one with Fatal Familial Insomnia — to accelerate prion disease research. Provides educational resources, connects at-risk individuals and families with researchers, and advocates for research funding and prevention trials.
Glycopyrrolate: A medication used in the late stages of CJD to reduce excess secretions (saliva, respiratory secretions). It works by blocking the nerve signals that stimulate glandular secretion. Often used in hospice care to manage “terminal secretions” (the “death rattle”) and reduce aspiration risk.
Autoimmune encephalitis: A condition in which the immune system attacks the brain. It can look like CJD but is often treatable, which is why it must be tested for and ruled out before a CJD diagnosis is accepted.

Sources & Key References

This patient guide is written in plain language and deliberately keeps medical citations light. The points above draw on published medical literature, international CJD diagnostic criteria and surveillance reports, and guidance from prion-disease centers and the CJD Foundation. A few of the key peer-reviewed references are listed below for families who wish to read further; the corresponding clinical guide for healthcare professionals contains fuller referencing.

Zerr I and colleagues, Brain, 2009 — updated diagnostic criteria for sporadic CJD (PMID: 19773352).
Hermann P and colleagues, Lancet Neurology, 2021 — biomarkers and diagnostic guidelines in prion disease (PMID: 33609480).
Watson N and colleagues, Nature Reviews Neurology, 2021 — international surveillance and the importance of registries (PMID: 33972773).
Zerr I and colleagues, Nature Reviews Disease Primers, 2024 — comprehensive overview of Creutzfeldt-Jakob disease (PMID: 38424082).
Bongianni M and colleagues, JAMA Neurology, 2017 — RT-QuIC for the diagnosis of CJD (PMID: 27942718).
Orrú CD and colleagues, New England Journal of Medicine, 2014 — a nasal-brushing RT-QuIC test for prion disease (PMID: 25099576).
Geschwind MD, Continuum, 2015 — a clinical review of prion diseases (PMID: 26633779).
Haïk S and colleagues, Lancet Neurology, 2014 — the randomized trial showing doxycycline did not extend survival (PMID: 24411709).
Mead S and colleagues, Lancet Neurology, 2026 — genetic prion disease and emerging prion-lowering approaches (PMID: 41579904).
Parchi P and colleagues, Brain, 1999 — landmark classification of sporadic CJD molecular subtypes by codon 129 genotype and PrP-Sc type, establishing the framework still used for prognosis and research today.
Orrú CD and colleagues, New England Journal of Medicine, 2014 — demonstrated that RT-QuIC on olfactory mucosal brushings (nasal swabs) achieves very high sensitivity and specificity for CJD without lumbar puncture (PMID: 25099576).
Haïk S and colleagues, Lancet Neurology, 2014 — the definitive phase 2, randomized, double-blind trial of doxycycline in sporadic CJD: 121 patients, no significant survival benefit (PMID: 24411709). The most rigorous clinical trial conducted in CJD to date.
Mead S and Reilly MM, Lancet Neurology, 2015 — comprehensive review of inherited prion diseases including FFI, GSS, and E200K familial CJD, with clinical and counseling guidance for at-risk families (PMID: 25792098).
CJD Foundation (cjdfoundation.org) — the primary patient and family organization for prion disease in the United States; operates the HelpLine (800-659-1991), family support programs, and caregiver resources referenced throughout this guide.
Prion Alliance (prionalliance.org) — nonprofit founded by genetic prion disease patients; advocates for research, connects families with research programs, and provides educational resources for people at risk of inherited prion disease.
National Prion Disease Pathology Surveillance Center, Case Western Reserve University (neuropathology.case.edu/prion) — the US reference center for prion disease diagnosis, surveillance, and neuropathology. Free diagnostic testing for suspected US cases: 216-368-0587.

For healthcare professionals, see the companion clinical guide: Creutzfeldt-Jakob Disease — Clinical Guide.

Questions to Ask Your Doctor — About Support & Planning

Can we be connected with a medical social worker to help with practical and financial needs?
How do we set up hospice and home-health support, and what will it cover where we live?
What advance-care-planning documents should we complete, and can someone help us do them correctly?
Is autopsy and brain donation through the national surveillance center something you can help us arrange — and what would it involve?
What national CJD surveillance unit or specialist center serves our area?
Are there specific precautions we should know about for any future medical or dental procedures?
Where can we find emotional support — counseling, chaplaincy, or a CJD family support group?
Who do we call, day or night, when we are worried or need help?

A Guide for Families FacingCreutzfeldt-Jakob & Prion Disease

⚡ Quick Start — If You Read Nothing Else

Understanding CJD & Prion Disease

Is It CJD — or Something Treatable?

The Four Main Types

What This Diagnosis Means

Questions to Ask Your Doctor — Getting Started

Symptoms & How CJD Differs From Other Dementias

The common early and progressing symptoms

The Subtypes in Detail

How Doctors Confirm CJD — A Hopeful, Practical Section

RT-QuIC — the most important modern test

MRI of the brain (with DWI)

Older spinal-fluid markers (14-3-3 and tau)

EEG (brain wave test)

Genetic (PRNP) testing

Brain tissue (neuropathology) — the only fully definitive test

Questions to Ask Your Doctor — About the Diagnosis

There Is No Cure — and Why Comfort Care Matters So Much

Symptom-by-Symptom Comfort Guide

Palliative Care & Hospice — Bring Them In Early

Palliative care

Hospice

Questions to Ask Your Doctor — About Care & Comfort

Research & Clinical Trials — An Honest Picture

Understanding How CJD Progresses: A Week-by-Week Guide for Families

Failed & De-Adopted Therapies — What Has Not Worked

Prion-Lowering (ASO) Research — The Most Promising Direction

Genetic Forms, Counseling & Pre-Symptomatic Testing

How inheritance works, in plain terms

Genetic counseling

The very personal decision of pre-symptomatic testing

Questions to Ask Your Doctor — About Research & Genetics

Caregiver Guidance — For the People Holding It All Together

Pace yourself for a fast, intense journey

Build a circle of support early

Caring for your own heart

Practical day-to-day tips

Transmission & Infection Control — What’s Safe (and What Families Worry About)

Everyday contact — safe

Where special precautions do apply

Blood and organ donation

Advance Care Planning

Understanding what hospice provides — and when to ask for it

Autopsy, Surveillance & the NPDPSC — Why It Helps Families and Research

Why families choose autopsy

The National Prion Disease Pathology Surveillance Center (NPDPSC)

Specialty Centers & Support Directory

International Access & Surveillance

Financial & Practical Resources

An Honest Conversation About Hope

Reproductive Considerations & CJD

For family members of reproductive age

Frequently Asked Questions

Glossary — Plain-Language Definitions

Sources & Key References

Questions to Ask Your Doctor — About Support & Planning

⚠️ Safety Warnings & Critical Drug Risks

Infection Control — CJD Prions Are Not Destroyed by Standard Sterilization

Symptom Management Safety & Advance Care Planning

A Guide for Families Facing
Creutzfeldt-Jakob & Prion Disease